Results
- Showing results for:
- Reset all filters
Search results
-
Journal articleRoseby W, Kettner H, Roseman L, et al., 2025,
Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies
, Frontiers in Psychology, ISSN: 1664-1078 -
Journal articlePronovost-Morgan C, Greenway KT, Roseman L, et al., 2025,
An international Delphi consensus for reporting of setting in psychedelic clinical trials
, Nature Medicine, Vol: 31, Pages: 2186-2195, ISSN: 1078-8956Psychedelic substances exhibit complex interactions with the ‘set and setting’ of use, that is, the mental state of the user and the environment in which a psychedelic experience takes place. Despite these contextual variables’ known importance, psychedelic research has lacked methodological rigor in reporting extra-pharmacological factors. This study aimed to generate consensus-based guidelines for reporting settings in psychedelic clinical research, according to an international group of psychedelic researchers, clinicians and past trial participants. We conducted a Delphi consensus study composed of four iterative rounds of quasi-anonymous online surveys. A total of 89 experts from 17 countries independently listed potentially important psychedelic setting variables. There were 770 responses, synthesized into 49 distinct items that were subsequently rated, debated and refined. The process yielded 30 extra-pharmacological variables reaching predefined consensus ratings:i.e., ‘important’ or ‘very important’ for ≥70% of experts. These items compose the Reporting of Setting in Psychedelic Clinical Trials (ReSPCT) guidelines, categorized into physical environment, dosing session procedure, therapeutic framework and protocol, and subjective experiences. Emergent findings reveal significant ambiguities in current conceptualizations of set and setting. The ReSPCT guidelines and accompanying explanatory document provide a new standard for the design and documentation of extra-pharmacological variables in psychedelic clinical research.
-
Journal articleWall MB, Demetriou L, Giribaldi B, et al., 2025,
Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression
, AMERICAN JOURNAL OF PSYCHIATRY, Vol: 182, Pages: 569-582, ISSN: 0002-953X- Cite
- Citations: 4
-
Journal articlePalacek K, Carhart-Harris R, Fabiano N, 2025,
The salience network is functionally twice as large in depression: The first depression biomarker?
, Genomic Psychiatry, Vol: 1, Pages: 18-20, ISSN: 2997-254X<jats:p> <jats:bold>This commentary examines recent findings demonstrating that individuals with depression exhibit a functionally expanded salience network compared to non-depressed controls. Neuroimaging data reveals this network expansion predates symptom onset and remains stable regardless of symptom severity or treatment interventions. The authors propose this distinctive neural signature as a potential biomarker for depression risk, enabling earlier identification and intervention. They discuss three potential mechanisms underlying this expansion: compensatory network changes, genetic predisposition, and relative expansion secondary to atrophy in other brain regions. The commentary emphasizes the need to conceptualize depression as a disorder of neural connectivity rather than isolated neurotransmitter imbalances, with implications for developing targeted therapeutic approaches.</jats:bold> </jats:p>
-
Journal articleAgnorelli C, Spriggs M, Godfrey K, et al., 2025,
Neuroplasticity and psychedelics: a comprehensive examination of classic and non-classic compounds in pre and clinical models
, Neuroscience and Biobehavioral Reviews, Vol: 172, ISSN: 0149-7634Neuroplasticity, the ability of the nervous system to adapt throughout an organism's lifespan, offers potential as both a biomarker and treatment target for neuropsychiatric conditions. Psychedelics, a burgeoning category of drugs, are increasingly prominent in psychiatric research, prompting inquiries into their mechanisms of action. Distinguishing themselves from traditional medications, psychedelics demonstrate rapid and enduring therapeutic effects after a single or few administrations, believed to stem from their neuroplasticity-enhancing properties. This review examines how classic psychedelics (e.g., LSD, psilocybin, N,N-DMT) and non-classic psychedelics (e.g., ketamine, MDMA) influence neuroplasticity. Drawing from preclinical and clinical studies, we explore the molecular, structural, and functional changes triggered by these agents. Animal studies suggest psychedelics induce heightened sensitivity of the nervous system to environmental stimuli (meta-plasticity), re-opening developmental windows for long-term structural changes (hyper-plasticity), with implications for mood and behavior. Translating these findings to humans faces challenges due to limitations in current imaging techniques. Nonetheless, promising new directions for human research are emerging, including the employment of novel positron-emission tomography (PET) radioligands, non-invasive brain stimulation methods, and multimodal approaches. By elucidating the interplay between psychedelics and neuroplasticity, this review informs the development of targeted interventions for neuropsychiatric disorders and advances understanding of psychedelics' therapeutic potential.
-
Journal articleCardone P, Alnagger NLN, Martial C, et al., 2025,
Psilocybin for disorders of consciousness: A case-report study
, CLINICAL NEUROPHYSIOLOGY, Vol: 173, Pages: 181-189, ISSN: 1388-2457- Cite
- Citations: 2
-
Journal articleTimmermann Slater CB, Sanders J, Reydellet D, et al., 2025,
Exploring 5-MeO-DMT as a pharmacological model for deconstructed consciousness
, Neuroscience of Consciousness, Vol: 2025, ISSN: 2057-21075-MeO-DMT is a short-acting psychedelic that is anecdotally reported to induce a radical disruption of the self and a paradoxical quality of aroused, waking awareness that is nevertheless devoid of any specific perceptual contents. Here, we conducted an exploratory observational study of the phenomenological and neuronal effects of this compound. We collected micro-phenomenological interviews, psychometric questionnaires, and electroencephalography (EEG) in naturalistic ceremonial settings where 5-MeO-DMT was ingested. Results revealed that the 5-MeO-DMT experience followed a dynamic progression that—only in the most extreme cases—manifested as a complete absence of self-experience and other phenomenal content with preserved awareness. Furthermore, visual imagery, bodily self-disruption, narrative self-disruption, and reduced phenomenal distinctions occurred in a variable fashion. EEG analyses revealed the 5-MeO-DMT experience was characterised by (global) alpha and (posterior) beta power reductions, implying a mode of brain functioning where top-down models are inhibited. Our preliminary phenomenological findings confirm the potential utility of 5-MeO-DMT as a pharmacological model for deconstructed consciousness while noting the limitations of employing retrospective questionnaires for this purpose. Considering the exploratory nature of this study and its limitations inherent to its naturalistic nature, further research employing real-time experience sampling and phenomenologically trained participants in controlled environments could expand our findings to meaningfully inform the potential of this tool for the scientific study of consciousness.
-
Journal articleSingleton SP, Timmermann C, Luppi AI, et al., 2025,
Network control energy reductions under DMT relate to serotonin receptors, signal diversity, and subjective experience
, COMMUNICATIONS BIOLOGY, Vol: 8 -
Journal articlePasquini L, Simon AJ, Gallen CL, et al., 2025,
Dynamic medial parietal and hippocampal deactivations under DMT relate to sympathetic output and altered sense of time, space, and the self
, IMAGING NEUROSCIENCE, Vol: 3- Cite
- Citations: 1
-
Journal articleHavenith MN, Leidenberger M, Brasanac J, et al., 2025,
Decreased CO<sub>2</sub> saturation during circular breathwork supports emergence of altered states of consciousness
, COMMUNICATIONS PSYCHOLOGY, Vol: 3- Cite
- Citations: 8
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.
